Revolution Medicines, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Revolution Medicines, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-53.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 73% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +190%In 3 years sales changed by -100% while total assets changed by +190%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-54.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 75% of Healthcare companies in United States.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 58% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
96%Of every $100 of net worth, $96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 82% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Revolution Medicines, Inc. made a loss over the last year. Revolution Medicines, Inc. owes $0.40 for every $1 it owns. Revolution Medicines, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRevolution Medicines, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
15.38The share price is 15.38 times Revolution Medicines, Inc.'s book value per share, higher than 91% of Healthcare companies in United States.
Market cap
$40.1 BThe total market value of all of Revolution Medicines, Inc.'s shares at today's price (share price × number of shares), larger than 96% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$2.6 BWhat Revolution Medicines, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$12.16Net worth divided by the number of shares. The share price of $186.99 is 15.4 times this, which is the P/B above.
Return on equity (ROE)
-79.1%Revolution Medicines, Inc. lost 79.1% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
Owes vs Owns
0.40×Revolution Medicines, Inc. owes $0.40 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Dividend yield
NoneRevolution Medicines, Inc. does not currently pay a dividend.
Profit growth
LossRevolution Medicines, Inc. made a loss in each of the last two years.
Interest cover
Not coveredRevolution Medicines, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashRevolution Medicines, Inc. held $1.9 B more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Revolution Medicines, Inc.: $40.1 B ÷ $2.6 B (30 Jun 2026) = 15.4.
What is Revolution Medicines, Inc.'s return on equity?
Revolution Medicines, Inc. lost 79.1% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
How much does Revolution Medicines, Inc. owe compared with what it owns?
Revolution Medicines, Inc. owes $0.40 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Does Revolution Medicines, Inc. pay a dividend?
No. Revolution Medicines, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.